COMMUNIQUÉS West-GlobeNewswire
-
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025
31/03/2026 -
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
31/03/2026 -
EssilorLuxottica et Meta élargissent leur portefeuille de lunettes IA avec les modèles Ray-Ban Meta optiques
31/03/2026 -
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
31/03/2026 -
Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026 -
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026 -
Spinal Rehab & Sports Medicine Expands Impact in Austin with Elite University Partnerships and Growing Presence Across Local Athletic Communities
31/03/2026 -
Betterbrand's BetterLungs Mullein + Chlorophyll Shows Significant Respiratory and Fatigue Improvements in 60-Day Clinical Study
31/03/2026 -
Mike Tyson and TerrAscend Expand TYSON 2.0 Footprint into Pennsylvania and Maryland
31/03/2026 -
Lighthouse Autism Center Opening New Autism Therapy Center in Rocky Mount, North Carolina
31/03/2026 -
Global Medtech CDMO Market Grows to $96.5B in 2025 as Pharma-Medtech Convergence Emerges as a Defining Accelerator
31/03/2026 -
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
31/03/2026 -
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
31/03/2026 -
Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results
31/03/2026 -
Axiom Medical Signal Summit 2026 Showcases the Power of Early Action and Complete Case Management
31/03/2026 -
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026 -
BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System
31/03/2026 -
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
31/03/2026 -
ZymoChem's BAYSE™ Becomes First Bio-Based Superabsorbent to Match and Outperform Petroleum-Based Materials
31/03/2026
Pages